Psoriasis Disease Modification Following Long-term Treatment With An Il-17 Antagonist

Abstract

The present disclosure relates to methods for modifying the psoriasis disease course in particular patients having chronic plaque-type psoriasis and inhibiting the progression to psoriatic arthritis (PsA) in these patients, using IL-17 antagonists, e.g., secukinumab. Also disclosed herein are uses of IL-17 antagonists, e.g., IL-17 antibodies, such as secukinumab, for use in modifying the psoriasis disease course in particular patients having chronic plaque-type psoriasis and inhibiting the progression to PsA in these patients, as well as medicaments, dosing regimens, pharmaceutical formulations, dosage forms, and kits for use in the disclosed uses and methods.


Claims

Sign in to the Lens

Feedback